Login to Your Account

Clinic Roundup

Monday, July 11, 2011
Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, of Basel, Switzerland, said Phase III results showed that more than one-third of patients taking mTOR inhibitor Afinitor (everolimus) experienced a 50 percent or greater reduction in the size of their subependymal giant cell astrocytomas, noncancerous brain tumors associated with tuberous sclerosis. Data were presented at the TSC Research conference in Washington.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription